Education
About Us
Working with TipRanks
Follow Us
Argent Biopharma (RGTLF)
OTHER OTC:RGTLF
RGTLF Stock Chart & Stats
$0.10
$0.00(0.00%)
At close: 4:00 PM EST
$0.10
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.15
Previous CloseN/A
Volume49.00
Average Volume (3M)314.00
Market Cap
$2.87M
Enterprise Value$11.22M
Total Cash (Recent Filing)$1.02M
Total Debt (Recent Filing)$8.29M
Price to Earnings (P/E)―
Beta-0.79
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding87,942,314
10 Day Avg. Volume254
30 Day Avg. Volume314
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap3.91
Enterprise Value/Revenue97.45
Enterprise Value/Gross Profit-137.34
Enterprise Value/Ebitda-3.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross Margin ImprovementA material gross margin improvement in 2025 implies better product mix or pricing power that can sustainably raise per-unit economics. If management sustains mix/pricing gains, margins can underpin a path to profitability once scale or revenue stabilizes, improving long-term viability.
Less Negative Free Cash Flow TrendAn improvement in free cash flow versus the prior year, even if still negative, shows progress toward reducing cash burn. Continued improvement reduces reliance on external financing and supports runway extension, making a durable operational recovery more feasible if trends continue.
Reported Revenue And EPS Growth MetricsReported positive revenue and EPS growth metrics signal potential recent inflection in top-line and per-share performance. If these growth figures reflect sustainable demand or operational leverage, they could mark the start of a multi-quarter recovery that materially improves fundamentals over months.
Bears Say
Negative Shareholders' EquityNegative shareholders' equity over multiple years signals capital deficiency and structural balance-sheet weakness. It limits financial flexibility, raises default and covenant risk, and typically forces reliance on dilutive or costly external funding, undermining long-term capital stability.
Persistent Cash Burn And Zero Operating Cash FlowConsistent, material negative free cash flow and zero reported operating cash flow indicate the business is not self-funding and must repeatedly access financing. This persistent cash burn erodes runway, increases refinancing risk, and constrains investment in R&D or commercialization over the medium term.
Sharply Contracting Revenue And Deep LossesA multi-year sharp revenue contraction combined with deep operating losses shows loss of scale and insufficient revenue to cover fixed costs. This structural earnings weakness makes margin recovery harder, increases per-unit costs, and heightens the need for durable demand or cost restructuring to restore profitability.
Argent Biopharma News
RGTLF FAQ
What was Argent Biopharma’s price range in the past 12 months?
Argent Biopharma lowest stock price was $0.01 and its highest was $0.15 in the past 12 months.
What is Argent Biopharma’s market cap?
Argent Biopharma’s market cap is $2.87M.
When is Argent Biopharma’s upcoming earnings report date?
Argent Biopharma’s upcoming earnings report date is Aug 27, 2026 which is in 161 days.
How were Argent Biopharma’s earnings last quarter?
Argent Biopharma released its earnings results on Feb 27, 2026. The company reported -$0.027 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.027.
Is Argent Biopharma overvalued?
According to Wall Street analysts Argent Biopharma’s price is currently Overvalued.
Does Argent Biopharma pay dividends?
Argent Biopharma does not currently pay dividends.
What is Argent Biopharma’s EPS estimate?
Argent Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argent Biopharma have?
Argent Biopharma has 87,942,314 shares outstanding.
What happened to Argent Biopharma’s price movement after its last earnings report?
Argent Biopharma reported an EPS of -$0.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Argent Biopharma?
Currently, no hedge funds are holding shares in RGTLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argent Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.17%
12-Months-Change
Fundamentals
Return on Equity
258.94%
Trailing 12-Months
Asset Growth
-29.21%
Trailing 12-Months
Company Description
Argent Biopharma
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer's. It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and R&D, which focuses on wound treatment. The company has collaborated with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.
Technical Analysis
Genetic Technologies
―
Zelira Therapeutics
―
EVE Health Group Limited
―
Adherium Ltd.
―
Bio-Gene Technology Ltd.
―